Belite Bio to Join Webinar on Stargardt Disease, Geographic Atrophy, and Tinlarebant

Belite Bio, LLC. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing novel treatments for degenerative retinal diseases, announced its participation in a Key Opinion Leader Webinar. The event, organized by Cantor Fitzgerald, will take place on Monday, May 13, 2024, at 2:00 p.m. ET.

The webinar will be moderated by Jennifer Kim, Director of Equity Research at Cantor Fitzgerald, and will feature Dr. Michel Michaelides, a leading expert in inherited eye diseases. Dr. Michaelides holds prestigious positions at the University College London Institute of Ophthalmology and Moorfields Eye Hospital. He will discuss the critical need for effective treatments for Stargardt disease (STGD1) and Geographic Atrophy (GA), both of which are areas of significant unmet medical need.

In his presentation, Dr. Michaelides will provide an overview of the current treatment landscape for these conditions. He will highlight the real-world applications of Belite Bio’s lead candidate, Tinlarebant, particularly in treating STGD1 and GA. Additionally, he will analyze data from Belite’s Phase 2 clinical trial on STGD1, which was recently published at the Association for Research in Vision and Ophthalmology (ARVO).

Tinlarebant (LBS-008) is an innovative, once-daily oral medication designed to inhibit retinol binding protein 4 (RBP4). This mechanism helps reduce the accumulation of vitamin-A based toxins in the eye, which are linked to the onset and progression of STGD1 and the progression of GA, an advanced form of dry age-related macular degeneration (AMD). The drug has received multiple designations from regulatory authorities, including Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1.

Dr. Michelides is well-recognized in his field, serving as a Professor of Ophthalmology and a Consultant Ophthalmologist. His expertise spans Medical Retina, Inherited Eye Disease, and Pediatric Ophthalmology. He has been instrumental in advancing gene and stem cell therapy research at UCL and is a founding member of a UCL gene therapy spin-out company. His accolades include awards from the Foundation Fighting Blindness and the Department of Health/HEFCE. With over 400 peer-reviewed publications and 35 book chapters, Dr. Michaelides' research includes multiple international studies and ongoing retinal clinical trials exploring new therapies.

Belite Bio’s primary focus is on addressing degenerative retinal diseases such as STGD1 and GA, as well as certain metabolic diseases. Their lead candidate, Tinlarebant, is being tested in several clinical trials, including the Phase 3 DRAGON study, the Phase 2/3 DRAGON II study for adolescent STGD1 subjects, and the Phase 3 PHOENIX study for GA subjects.

By advancing these trials, Belite Bio aims to provide new therapeutic options for patients with these challenging conditions. The upcoming webinar offers a platform to share crucial insights and progress in these efforts.